Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Jabbour, Elias; Oehler, Vivian G.; Koller, Paul B.; Jamy, Omer; Lomaia, Elza; Hunter, Anthony M.; Uspenskaya, Olga; Samarina, Svetlana; Mukherjee, Sudipto; Cortes, Jorge E.; Baer, Maria R.; Zherebtsova, Vera; Shuvaev, Vasily; Turkina, Anna; Davydkin, Igor; Guo, Huanshan; Chen, Zi; Fu, Tommy; Jiang, Lixin; Wang, Cunlin; Wang, Hengbang; Yang, Dajun; Zhai, Yifan; Kantarjian, Hagop

doi:10.1001/jamaoncol.2024.5157

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Importance Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant or intolerant to BCR-ABL1 tyrosine kinase inhibitors (TKIs) have limited treatment options. Olverembatinib, which is approved in China, has only been tested in …